Bill Sibold, Madrigal Pharmaceuticals CEO , joins 'Fast Money' to talk quarterly results.

With shortstop Nick Madrigal due for a long absence with a fractured shoulder, the Mets could reunite with a fan favorite ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported two-year results from the open-label compensated MASH cirrhosis (F4c) ...

WEST CONSHOHOCKEN, Pa. (AP) — WEST CONSHOHOCKEN, Pa. (AP) — Madrigal Pharmaceuticals Inc. (MDGL) on Wednesday reported a loss of $59.4 million in its fourth quarter. The West Conshohocken, ...

Investing.com -- Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: NASDAQ: MDGL) rose 17% following the announcement of their fourth-quarter and full-year 2024 financial results, which included a ...

Madrigal Pharmaceuticals (MDGL) reported positive two-year results from the open-label compensated MASH cirrhosis arm of the Phase 3 ...

Madrigal Pharmaceuticals (MDGL) reported Q4 results and provided a 2-year update from the open-label metabolic dysfunction-associated ...

The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...

Madrigal Pharmaceuticals MDGL reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus ...

Mets insider Anthony DiComo noted that Madrigal’s injury has significantly improved Walton’s chances of making the Opening ...